2,042 Shares in Natera, Inc. (NASDAQ:NTRA) Purchased by Whalen Wealth Management Inc.

Whalen Wealth Management Inc. acquired a new position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 2,042 shares of the medical research company's stock, valued at approximately $289,000.

Other institutional investors and hedge funds have also modified their holdings of the company. LRI Investments LLC bought a new stake in Natera in the 4th quarter valued at $29,000. Rakuten Securities Inc. boosted its position in shares of Natera by 117.8% during the 1st quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock valued at $31,000 after acquiring an additional 119 shares in the last quarter. ORG Partners LLC bought a new stake in Natera in the first quarter valued at about $32,000. Blue Trust Inc. raised its position in Natera by 223.7% in the fourth quarter. Blue Trust Inc. now owns 301 shares of the medical research company's stock worth $48,000 after purchasing an additional 208 shares in the last quarter. Finally, EverSource Wealth Advisors LLC raised its position in Natera by 372.9% in the fourth quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company's stock worth $52,000 after purchasing an additional 261 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, insider Solomon Moshkevich sold 3,000 shares of the stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $140.48, for a total transaction of $421,440.00. Following the completion of the transaction, the insider now owns 141,782 shares in the company, valued at approximately $19,917,535.36. This represents a 2.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Steven Leonard Chapman sold 9,563 shares of the business's stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $138.41, for a total value of $1,323,614.83. Following the transaction, the chief executive officer now directly owns 212,541 shares in the company, valued at $29,417,799.81. This trade represents a 4.31% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 59,755 shares of company stock valued at $8,898,589 in the last 90 days. 7.60% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. Robert W. Baird lifted their price objective on Natera from $183.00 to $188.00 and gave the company an "outperform" rating in a report on Friday, February 28th. Wall Street Zen lowered Natera from a "hold" rating to a "sell" rating in a research note on Saturday, May 17th. BTIG Research reiterated a "buy" rating on shares of Natera in a research report on Friday, February 28th. UBS Group upped their price objective on shares of Natera from $211.00 to $218.00 and gave the stock a "buy" rating in a research note on Friday, May 9th. Finally, Morgan Stanley increased their price target on Natera from $176.00 to $185.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. One analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $184.63.

Natera Trading Up 2.4%

Shares of NTRA traded up $4.01 on Thursday, reaching $168.17. 1,444,597 shares of the company's stock were exchanged, compared to its average volume of 1,415,253. The business has a 50 day moving average price of $158.53 and a two-hundred day moving average price of $158.58. Natera, Inc. has a 12 month low of $92.14 and a 12 month high of $183.00. The stock has a market capitalization of $22.96 billion, a P/E ratio of -114.40 and a beta of 1.74.

Natera (NASDAQ:NTRA - Get Free Report) last released its earnings results on Thursday, May 8th. The medical research company reported ($0.50) EPS for the quarter, topping analysts' consensus estimates of ($0.59) by $0.09. Natera had a negative net margin of 10.36% and a negative return on equity of 18.29%. The firm had revenue of $501.83 million during the quarter, compared to analyst estimates of $446.68 million. During the same quarter in the previous year, the business earned ($0.56) EPS. The business's quarterly revenue was up 36.5% compared to the same quarter last year. Equities research analysts predict that Natera, Inc. will post -1.49 EPS for the current year.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.